This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Academic Research Centers Join Forces To Improve Clinical Research

MADISON, Wis., March 7, 2013 /PRNewswire/ -- A collaborative group of academic research organizations is revolutionizing the way clinical research is conducted through their participation in the Research Resonance Network. The network's host, Forte Research Systems, Inc., has announced the availability of a new online home for the group along with a suite of tools for improving clinical research processes. Registration is now open to access the first resource to go live on the network, the Site Metrics Registry. This registry is the culmination of seven years of effort driven, in large part, by 20 leading academic medical centers including the Yale Center for Clinical Investigation and Indiana University Simon Cancer Center.


There is a growing interest in improving the processes around clinical study execution. Most stakeholders in the drug development industry agree that the current environment is not sustainable. Similarly, the National Cancer Institute and the National Center for Advancing Translational Sciences have undertaken major efforts for process improvement as they seek avenues for speeding up the development of new therapies.

"A cursory glance at the current drug development landscape reveals ever-increasing unhealthy trends. Protocols are getting more complicated, study startup is labor intensive and inefficient, and centers face challenges in everything from compliance to financial viability," said Srini Kalluri, Forte's founder, president, CEO and Chief Customer Officer. "By allowing centers to share, compare, and take action based on their data, the Research Resonance Network helps centers work together to find better solutions."

The desire for improvement is evident in such initiatives as TransCelerate BioPharma, Inc., the Clinical Trials Transformation Initiative (CTTI), and the Alliance for Clinical Research Excellence and Safety (ACRES), all of which strive to bring key stakeholders together to find ways to improve clinical research.

Under the leadership provided by the participating centers, the Research Resonance Network Site Metrics Registry, hosted at, is already delivering value with its library of standard data definitions for a large number of performance measurements, also referred to as "metrics." The registry contains metrics for: evaluating cycle times in such areas as IRB approval and contracting; measuring the size of clinical research operations in such areas as the number of open protocols and new subject accruals; and measuring effort in areas that include data management and budgeting.

"We've taken the initiative to work with Forte on this effort because we believe it's an invaluable tool for academic medical centers and Clinical and Translational Science Award (CTSA) sites. Knowing how our peer institutions are doing helps us to improve our own clinical research processes and timelines," said Robert Sherwin, MD, CNH, Long Professor of Medicine at the Yale School of Medicine and director of the Yale Center of Clinical Investigation. 

Using sophisticated security mechanisms, the registry allows centers to contribute their data and then compare their own performance to anonymous data aggregated from their peers. Forte acts as the trusted third party ensuring that the privacy of all participants is protected and nothing is ever shared with unauthorized individuals or in any way that allows the participating centers to be identified.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs